Phenotypic screen quantifying differential regulation of cardiac myocyte hypertrophy identifies CITED4 regulation of myocyte elongation

Journal of Molecular and Cellular Cardiology

Volumn 72, Issue , 2014, Pages 74-84

  Ryall, Karen A ^a   Bezzerides, Vassilios J ^b   Rosenzweig, Anthony ^c   Saucerman, Jeffrey J ^a  

^a University of Virginia   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiac hypertrophy; Cardiac myocytes; CITED4; CTGF; Phenotypic screen; Signal transduction

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; CITED4 PROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; MESSENGER RNA; PROTEIN BAX; REGULATOR PROTEIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SERCA2A PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANGIOTENSIN II; BAX PROTEIN, RAT; CEBPB PROTEIN, RAT; CTGF PROTEIN, RAT; NEU DIFFERENTIATION FACTOR; NRG1 PROTEIN, RAT;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL ELONGATION; CELL PROLIFERATION; CELL SHAPE; CELL SIZE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HEART MUSCLE CELL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; UPREGULATION; ANIMAL; CARDIOMEGALY; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II; ANIMALS; ANIMALS, NEWBORN; BCL-2-ASSOCIATED X PROTEIN; CARDIOMEGALY; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL SHAPE; CONNECTIVE TISSUE GROWTH FACTOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MYOCYTES, CARDIAC; NEUREGULIN-1; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901236111     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.02.013     Document Type: Article

References (64)

1. Hill J.A., Olson E.N. Cardiac plasticity. N Engl J Med 2008, 358:1370-1380.
2. Levy D., Garrison R., Savage D., Kannel W., Castelli W. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561-1566.
3. Okin P.M., Devereux R.B., Jern S., Kjeldsen S.E., Julius S., Nieminen M.S., et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004, 292:2343-2349.
4. Haider A.W., Larson M.G., Benjamin E.J., Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998, 32:1454-1459.
5. Berlo J.H.V., Maillet M., Molkentin J.D. Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest 2013, 123:37-45.
6. Maillet M., Van Berlo J.H., Molkentin J.D. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat Rev Mol Cell Biol 2013, 14:38-48.
7. Bernardo B.C., Weeks K.L., Pretorius L., McMullen J.R. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 2010, 128:191-227.
8. Grossman W., Jones D., McLaurin L.P. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975, 56:56-64.
9. Berenji K., Drazner M.H., Rothermel B.A., Hill J.A. Does load-induced ventricular hypertrophy progress to systolic heart failure?. Am J Physiol Heart Circ Physiol 2005, 289:H8-H16.
10. Burchfield J.S., Xie M., Hill J.A. Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation 2013, 128:388-400.
11. Bass G.T., Ryall K.A., Katikapalli A., Taylor B.E., Dang S.T., Acton S.T., et al. Automated image analysis identifies signaling pathways regulating distinct signatures of cardiac myocyte hypertrophy. J Mol Cell Cardiol 2011, 52:923-930.
12. Molkentin J.D. The transcription factor C/EBPbeta serves as a master regulator of physiologic cardiac hypertrophy. Circ Res 2011, 108:277-278.
13. Kehat I., Davis J., Tiburcy M., Accornero F., Saba-El-Leil M.K., Maillet M., et al. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res 2011, 108:176-8314.
14. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006, 7:589-600.
15. Kehat I., Molkentin J.D. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 2010, 122:2727-2735.
16. Ryall K.A., Holland D.O., Delaney K.A., Kraeutler M.J., Parker A.J., Saucerman J.J. Network reconstruction and systems analysis of cardiac myocyte hypertrophy signaling. J Biol Chem 2012, 287:42259-42268.
17. Prasad K.M., Xu Y., Yang Z., Acton S.T., French B.A. Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution. Gene Ther 2010, 18:43-52.
18. Ryall K.A., Saucerman J.J. Automated imaging reveals concentration dependent delay in reversibility of cardiac myocyte hypertrophy. J Mol Cell Cardiol 2012, 53:282-290.
19. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008, 3:1101-1108.
20. Sachs K., Perez O., Pe'er D., Lauffenburger D.a, Nolan G.P. Causal protein-signaling networks derived from multiparameter single-cell data. Science 2005, 308:523-529.
21. Izu L.T., Chen-Izu Y. Une cellule type?. J Mol Cell Cardiol 2012, 52:921-922.
22. Whelan R.S., Konstantinidis K., Wei A.C., Chen Y., Reyna D.E., Jha S., et al. Bax regulates primary necrosis through mitochondrial dynamics. Proc Natl Acad Sci U S A 2012, 109:6566-6571.
23. Crow M.T., Mani K., Nam Y.-J., Kitsis R.N. The mitochondrial death pathway and cardiac myocyte apoptosis. Circ Res 2004, 95:957-970.
24. Nadal-Ginard B. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res 2003, 92:139-150.
25. Boström P., Mann N., Wu J., Quintero P.A., Plovie E.R., Panáková D., et al. C/EBPβ controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 2010, 143:1072-1083.
26. Shiojima I., Sato K., Izumiya Y., Schiekofer S., Ito M., Liao R., et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005, 115:2108-2118.
27. Periasamy M., Huke S. SERCA pump level is a critical determinant of Ca(2+)homeostasis and cardiac contractility. J Mol Cell Cardiol 2001, 33:1053-1063.
28. Kuwahara K., Saito Y., Takano M., Arai Y., Yasuno S., Nakagawa Y., et al. NRSF regulates the fetal cardiac gene program and maintains normal cardiac structure and function. EMBO J 2003, 22:6310-6321.
29. Freund C., Schmidt-Ullrich R., Baurand A., Dunger S., Schneider W., Loser P., et al. Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 2005, 111:2319-2325.
30. Sun M., Chen M., Dawood F., Zurawska U., Li J.Y., Parker T., et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 2007, 115:1398-1407.
31. Nian M., Lee P., Khaper N., Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004, 94:1543-1553.
32. Kemp T.J., Aggeli I.K., Sugden P.H., Clerk A. Phenylephrine and endothelin-1 upregulate connective tissue growth factor in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2004, 37:603-606.
33. Tirziu D., Giordano F.J., Simons M. Cell communications in the heart. Circulation 2010, 122:928-937.
34. Baines C.P., Molkentin J.D. Adenine nucleotide translocase-1 induces cardiomyocyte death through upregulation of the pro-apoptotic protein Bax. J Mol Cell Cardiol 2009, 46:969-977.
35. Del Re D.P., Miyamoto S., Brown J.H. RhoA/Rho Kinase up-regulate bax to activate a mitochondrial death pathway and induce cardiomyocyte apoptosis. J Biol Chem 2007, 282:8069-8078.
36. Smith R.M., Suleman N., Lacerda L., Opie L.H., Akira S., Chien K.R., et al. Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovasc Res 2004, 63:611-616.
37. Kubli D.A., Ycaza J.E., Gustafsson A.B.. Bnip3 mediates mitochondrial dysfunction and cell death through Bax and Bak. Biochem J 2007, 405:407-415.
38. Mangan S., Alon U. Structure and function of the feed-forward loop network motif. Proc Natl Acad Sci U S A 2003, 100:11980-11985.
39. Cook S.A., Clerk A., Sugden P.H. Are transgenic mice the "alkahest" to understanding myocardial hypertrophy and failure?. J Mol Cell Cardiol 2009, 46:118-129.
40. Natarajan M., Lin K.M., Hsueh R.C., Sternweis P.C., Ranganathan R. A global analysis of cross-talk in a mammalian cellular signalling network. Nat Cell Biol 2006, 8:571-580.
41. Jentzsch C., Leierseder S., Loyer X., Flohrschütz I., Sassi Y., Hartmann D., et al. A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol 2012, 52:13-20.
42. Jaba I.M., Zhuang Z.W., Li N., Jiang Y., Martin K.A., Sinusas A.J., et al. NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth. J Clin Invest 2013, 123:1718-1731.
43. Kwak H.B., Song W., Lawler J.M. Exercise training attenuates age-induced elevation in Bax/Bcl-2 ratio, apoptosis, and remodeling in the rat heart. FASEB J 2006, 20:791-793.
44. Misao J., Hayakawa Y., Ohno M., Kato S., Fujiwara T., Fujiwara H. Expression of bcl-2 protein, an inhibitor of apoptosis, and Bax, an accelerator of apoptosis, in ventricular myocytes of human hearts with myocardial infarction. Circulation 1996, 94:1506-1512.
45. Dorn G.W. Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc Res 2009, 81:465-473.
46. Hayakawa Y., Chandra M., Miao W., Shirani J., Brown J.H., Dorn G.W., et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation 2003, 108:3036-3041.
47. Creemers E.E., Pinto Y.M. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 2011, 89:265-272.
48. Assayag P., Carré F., Chevalier B., Delcayre C., Mansier P., Swynghedauw B. Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis. Cardiovasc Res 1997, 34:439-444.
49. Rupérez M., Lorenzo O., Blanco-Colio L.M., Esteban V., Egido J., Ruiz-Ortega M. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 2003, 108:1499-1505.
50. Hishikawa K., Oemar B.S., Tanner F.C., Nakaki T., Luscher T.F., Fujii T. Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J Biol Chem 1999, 274:37461-37466.
51. Hishikawa K., Nakaki T., Fujii T. Connective tissue growth factor induces apoptosis via caspase 3 in cultured human aortic smooth muscle cells. Eur J Pharmacol 2000, 392:19-22.
52. Hishikawa K., Oemar B.S., Tanner F.C., Nakaki T., Fujii T., Luscher T.F. Overexpression of connective tissue growth factor gene induces apoptosis in human aortic smooth muscle cells. Circulation 1999, 100:2108-2112.
53. Dean R.G., Balding L.C., Candido R., Burns W.C., Cao Z., Twigg S.M., et al. Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem 2005, 53:1245-1256.
54. Mangan S., Itzkovitz S., Zaslaver A., Alon U. The incoherent feed-forward loop accelerates the response-time of the gal system of Escherichia coli. J Mol Cell Cardiol 2006, 356:1073-1081.
55. Kuramochi Y., Guo X., Sawyer D.B. Neuregulin activates erbB2-dependent src / FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 2006, 41:228-235.
56. García-Rivello H., Taranda J., Said M., Cabeza-Meckert P., Vila-Petroff M., Scaglione J., et al. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am J Physiol Heart Circ Physiol 2005, 289:H1153-H1160.
57. Sawyer D.B., Caggiano A. Neuregulin-1β for the treatment of systolic heart failure. J Mol Cell Cardiol 2011, 51:501-505.
58. Velagaleti R.S., Gona P., Pencina M.J., Aragam J., Wang T.J., Levy D., et al. Left ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction. Am J Cardiol 2014, 113:117-122.
59. Kehat I., Davis J., Tiburcy M., Accornero F., Saba-El-Leil M.K., Maillet M., et al. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res 2011, 108:176-183.
60. Nicol R.L., Frey N., Pearson G., Cobb M., Richardson J., Olson E.N. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J 2001, 20:2757-2767.
61. Sciaretta S., Sadoshima J. New insights into the molecular phenotype of eccentric hypertrophy. J Mol Cell Cardiol 2010, 49:153-156.
62. Nakaoka Y., Shioyama W., Kunimoto S., Arita Y., Higuchi K., Yamamoto K., et al. SHP2 mediates gp130-dependent cardiomyocyte hypertrophy via negative regulation of skeletal alpha-actin gene. J Mol Cell Cardiol 2010, 49:157-164.
63. Langenickel T., Pagel I., Höhnel K., Dietz R., Carvajal J.A., Delpiano A.M., et al. Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure. Am J Physiol Heart Circ Physiol 2000, 278:H1500-H1506.
64. Gardner D. Natriuretic peptides: markers or modulators of cardiac hypertrophy?. Trends Endocrinol Metab 2003, 14:411-416.